Ashish Kacholia-Backed Engineering Stock Surges 3.68%; Q4FY26 Profit Jumps 40% YoY

Shaily Engineering Plastics' shares closed at ₹2,733.80, up 3.68% on the day. The movement came following the company's strong FY26 performance and the regulatory milestone for ShailyPen Neo. Trading volume for the session stood at 9.82 lakh shares, well above the 30-day average of 5.74 lakh shares, indicating strong investor conviction rather than routine market activity. 

Shaily Engineering Plastics Limited closed FY26 on a genuinely strong note; both financially and operationally. The company reported healthy profit growth for the fourth quarter, delivered its best-ever annual numbers, and announced a landmark regulatory milestone for its ShailyPen Neo drug delivery platform. Taken together, it was a quarter and a year that showed what the company has been quietly building towards for several years.

Q4FY26: Quarterly Performance Of Shaily Engineering Plastcis

For the quarter ended March 31, 2026, Shaily Engineering Plastics reported consolidated revenue from operations of ₹236.82 crore, up 8.7% YoY from ₹217.83 crore in Q4FY25. On a sequential basis, revenue was down 5.5% QoQ from ₹250.50 crore in Q3FY26, largely showing normalisation after a strong festive-season quarter.

Total income for Q4FY26, including other income of ₹3.67 crore, stood at ₹240.50 crore compared to ₹217.95 crore in Q4FY25, a growth of 10.3% YoY. Sequentially, total income was down 4.0% QoQ from ₹250.57 crore in Q3FY26.

Total expenses for Q4FY26 stood at ₹188.17 crore against ₹178.35 crore in Q4FY25 and ₹201.06 crore in Q3FY26.

Profit before Tax for Q4FY26 stood at ₹52.32 crore, up 32.1% YoY from ₹39.60 crore in Q4FY25 and up 5.7% QoQ from ₹49.51 crore in Q3FY26. PAT for Q4FY26 stood at ₹40.16 crore, up 40.5% YoY from ₹28.59 crore in Q4FY25 and up 7.4% QoQ from ₹37.38 crore in Q3FY26.

Full Year FY26 Performance Of Shaily Engineering Plastics

The annual numbers show a clearly landmark year for Shaily Engineering Plastics.

Revenue from operations for FY26 stood at ₹990.67 crore, up 25.9% on an annual basis from ₹786.80 crore in FY25; the company's highest ever annual revenue, crossing the ₹990 crore mark. Total income for FY26, including other income of ₹7.78 crore, stood at ₹998.45 crore compared to ₹789.12 crore in FY25, a growth of 26.5% on an annual basis.

Other expenses came in at ₹141.92 crore versus ₹83.03 crore in FY25. Total expenses for FY26 stood at ₹775.84 crore against ₹669.84 crore in FY25.

PBT for FY26 stood at ₹222.61 crore, up 86.6% on an annual basis from ₹119.28 crore in FY25 a number that stands out even against an already strong FY25. Total tax expense came in at ₹52.70 crore versus ₹26.16 crore in FY25.

PAT for FY26 came in at ₹169.91 crore, up 82.5% on an annual basis from ₹93.12 crore in FY25; the highest ever annual PAT recorded by the company.

Key Operational Highlight: ShailyPen Neo Receives Multi-Regulatory Approval

Beyond the financial numbers, the most significant development in Q4FY26 was one that carries long-term strategic weight. Shaily announced that its strategic partner Orbicular Pharmaceutical Technologies, in partnership with its customer, has launched a generic version of Semaglutide injection in Canada, incorporating Shaily's proprietary ShailyPen Neo spring-driven pen injector platform. The combination product has been commercially available in India since March 2026 and has received USFDA Tentative Approval, Health Canada Notice of Compliance, and Indian CDSCO regulatory approval.

Dividend Declaration

The board has recommended a final dividend of ₹3/- per equity share of ₹2/- each, representing 150%, for the year ended March 31, 2026, subject to shareholder approval at the forthcoming Annual General Meeting.

Fund Raising Plan Approved By Board

Apart from the strong operational and financial performance, Shaily Engineering Plastics' board also approved an enabling resolution to raise up to ₹500 crore in one or more tranches through permissible routes including private placement, preferential issue, rights issue, Qualified Institutional Placement (QIP), or other methods allowed under applicable law.

Management Commentary

Amit Sanghvi, Managing Director, Shaily Engineering Plastics Limited, said:

"This achievement is one we carry with a great deal of humility. ShailyPen Neo did not happen by accident — spring-driven pen injector technology sits within a highly restricted IP environment, and bringing a platform of this calibre to regulatory approval was never going to be easy. We recognised early that spring-actuated pen injectors would become a critical enabler in injectable therapies and made a genuinely bold bet: full-scale investment from design through to industrial manufacturing. What got us here was not boldness alone — it was patience, precision, and an unshakeable belief in what we were building. I am deeply grateful to our customers who believed in us and chose to build with us — your confidence in Shaily has pushed us to be better at every step."

About Shaily Engineering Plastics Limited

Shaily Engineering Plastics Limited operates across three major industry verticals, specialising in manufacturing high precision components and assemblies using high performance engineering polymers. Shaily's healthcare business specifically specialises in the design, development, and precision manufacturing of complex drug delivery systems such as pen injectors, autoinjectors, and specialty drug delivery devices for global pharmaceutical companies. 

Share your thoughts in the comments below.

Disclaimer: This article is for informational purposes only and not investment advice.